Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

One last try: it is ASCO 2018 , and someone at the podium is detailing responses to the recently completed dose escalation 1B phase of the Kevetrin /Doxorubicin trial for ovarian cancer.

The data show excellent safety results

The data also show that 10% of patients had a 20% decrease in CA-125 and 15% had stable disease for 3 months.

As part of the 1B, when there was excellent safety but little response, the k dose was doubled and K was given 4x weekly, along with maximal Doxorubicin dose, but there was still no change in patient response.

Does the trial proceed? No. Was safety demonstrated- of course. Was efficacy one of the aims of the 1B part of the 1B/2 study? No, safety was the endpoint.

Nonetheless such data would not be good enough to proceed K p2 ovarian CA trial.

They can show safety but they will also have to demonstrate some efficacy. How much, I do not know. But it has to be